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Disclaimer: These standards and guidelines are designed primarily as an educational resource for clinical laboratory geneticists to
help them provide quality clinical laboratory genetic services. Adherence to these standards and guidelines does not necessarily
ensure a successful medical outcome. These standards and guidelines should not be considered inclusive of all proper procedures and
tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the
propriety of any specific procedure or test, the clinical molecular geneticist should apply his or her own professional judgment to the
specific clinical circumstances presented by the individual patient or specimen. It may be prudent, however, to document in the
laboratory record the rationale for any significant deviation from these standards and guidelines.
One mission of the ACMG Laboratory Quality Assurance
(QA) Committee is to develop standards and guidelines for
clinical genetics laboratories in an effort to maintain high
technical standards for the performance and interpretation
of genetic tests. This document was developed by the Ultra-
Rare Disorders (URD) Working Group under the auspices
of the Molecular Subcommittee of the Laboratory Quality
Assurance Committee. It is intended to provide laboratories
currently testing for ultra-rare disorders using molecular
methods, and those considering expanding their test menus
to include one or more such disorders, an overview of the
specific issues that arise when performing molecular diag-
nosis for disorders in which the test is available in only one
laboratory or very few laboratories. Specific issues that are
addressed include custom mutation analysis and prenatal
diagnosis, choice of analytic technique to identify private
mutations, concerns about test validation, and interpreta-
tion of results. Ultra-rare disorders requiring diagnostic
testing using cytogenetic or biochemical analyses are be-
yond the scope of this guideline and will be addressed in a
separate document.
URD 1 INTRODUCTION
URD 1.1 Under state and federal regulations, only licensed
clinical laboratories (i.e., certified under the Clinical Labora-
tory Improvement Amendments [CLIA]) are legally permitted
to perform testing on patients in which the results are released
directly to patients or their physicians and used for medical
management. This arrangement works well and is generally
adhered to throughout clinical practice, even for esoteric test-
ing areas such as molecular pathology and diagnostic molecu-
lar genetics. However, there is one gray area that persists and
has recently come under increased scrutiny at the federal level:
the transition of testing for ultra-rare disorders from the re-
search setting to the clinical setting. Testing for these disorders,
most of which are in the genetic disease area, has evolved this
way because: 1) typically only one or two laboratories in the world
are studying the causative gene, have recruited affected families
for study, and have become expert in the assays; and 2) the dis-
eases are too rare and the test requests too infrequent to generate
interest from a financial perspective among high-volume clinical
laboratories (hence, the term “ultra-rare” or “orphan” diseases).
URD 1.2 As a relatively new, translational area, lying at the
border between research and clinical service, ultra-rare disease
molecular genetic testing has few specific national standards
for quality assurance, quality control, test accessioning and
reporting, or proficiency evaluation. These matters have been
discussed by federally mandated agencies, including the Na-
tional Institute of Health (NIH)-Department of Energy (DOE)
Task Force on Genetic Testing and the Health and Human
Services (HHS) Secretary’s Advisory Committee on Genetic
Testing. The Task Force in particular devoted an entire portion
of its report to concerns over the regulatory status of orphan
genetic disease testing, and its final recommendations included
somewhat relaxed CLIA requirements for research laborato-
ries providing such services. 1
URD 1.3 As such tests now begin to make the transition from
research laboratories to those clinical laboratories with a will-
ingness to take them on, it has become evident that there is a
need for adaptation of existing quality assurance standards in
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molecular diagnostics to ultra-rare disease tests. These stan-
dards must be applicable to an almost infinite number of ana-
lytes (disease genes and mutations), and should enable the ef-
ficient translation of research-based tests to the clinical milieu,
the development of informed consent requirements as appro-
priate, and the construction of versatile tools for quality con-
trol, proficiency testing, results interpretation and reporting.
The purpose of these guidelines is to address this growing need.
URD 1.4 Evaluation of the Clinical Readiness of Genetic Test-
ing for a Rare Disorder
URD 1.4.1 An important issue in providing molecular diag-
nostic testing for an ultra-rare disorder is determining when
there is enough information to transition a test from the re-
search setting to a clinical diagnostic laboratory. This involves
an assessment of the clinical validity and clinical utility of the
test. Both clinical validity and clinical utility must be evaluated
for each test being considered for translation from a research
setting. Unfortunately, assessing these parameters is a chal-
lenge for rare disorders because of the paucity of data. How-
ever, the extremely low prevalence/incidence of a genetic dis-
order should not become a roadblock in making genetic testing
available to those patients and families for whom testing may
provide striking personal, family, and medical benefit. The dif-
ferences between a diagnostic test for a highly-penetrant dis-
order (the focus of this document) versus a predictive test for a
low-penetrant disorder should be considered.
URD 1.4.2 With that in mind, the following issues should be
considered in the determination of a clinical laboratory to offer
a molecular test for a rare genetic disorder:
URD 1.4.2.1. Does a review of the literature provide strong
evidence of the causative nature of mutations in the implicated
gene in the development of the rare genetic disease? (1) Is there
significant cosegregation of the gene mutation(s) with the phe-
notype, and absence of the mutation in clinically-unaffected
family members, providing high clinical sensitivity and speci-
ficity? (2) Is there evidence from functional studies of the mu-
tated gene product supporting causality with the disease phe-
notype? and/or (3) Have the findings from the initial reporting
laboratory been confirmed by other researchers, or has the data
from the initial reporting laboratory included multiple fami-
lies, groups of families, or patients from more than one popu-
lation, such that the conclusions can be generalized beyond a
very limited set of affected individuals?
URD 1.4.2.2. Do the benefits of a positive or negative test result
out-weigh the risks of undergoing the genetic test? Specifically,
is there evidence that the genetic test will provide information
relevant to diagnosis, prognosis, treatment, medical surveil-
lance, and family planning that will benefit the patient/family
having testing?
URD 1.4.3 Data relevant to the continued evaluation of the
clinical validity and utility of a genetic test for an ultra-rare
disorder will depend on the long-term collection and analysis
of additional data gained from clinical testing as well as from
further efforts in the research laboratory. Researchers and clin-
ical molecular diagnostic laboratories should be encouraged to
share such data as it becomes available.
URD 2 DEFINITIONS
URD 2.1 Ultra-rare disorder (URD): A disorder with preva-
lence of fewer than 200,000 individuals in the United States.
Some examples include pantothenate kinase-associated neu-
rodegeneration, X-linked ocular albinism, epidermolytic hy-
perkeratosis, adrenal hypoplasia congenita, ataxia telangiecta-
sia, X-linked myotubular myopathy, lissencephaly, and
Menkes disease.
URD 2.2 Mutation: A change from the normal sequence of a
gene which underlies a detrimental clinical presentation; a
change that is associated with disease.
URD 2.3 Variation: Any change from the normal sequence of a
gene. Variations may underlie a disease (e.g., mutation), or
may be unrelated to a disease process.
URD 2.4 Confirmation: A repeat analysis on a sample from an
individual. This may be done: 1) using a new independent
sample; 2) using another aliquot of DNA prepared from the
original submitted sample; or 3) using another method of anal-
ysis from the one used originally to identify the sequence vari-
ation.
URD 2.5 Positive control: A DNA sample that harbors a known
sequence change.
URD 2.6 Negative control: A DNA sample that is known to be
normal at the specific sequence position of interest.
URD 2.7 Analytical sensitivity: The proportion of biological
samples that have a positive test result or known mutation and
that are correctly classified as positive (assumes mutation is
tested for).
URD 2.8 Analytical specificity: The proportion of biological
samples that have a negative test result or no identified muta-
tion (being tested for) and that are correctly classified as neg-
ative.
URD 2.9 Clinical sensitivity: The proportion of individuals
who have (or will develop) the phenotype of interest and who
have a positive test result.
URD 2.10 Clinical specificity: The proportion of all unaffected
individuals identified by the proposed test as being negative.
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URD 2.11 Clinical utility: The value of a test, including risks
and benefits, for the purposes of confirmation of diagnosis in a
symptomatic patient, presymptomatic analysis, treatment,
family planning, and prenatal testing (when relevant).
URD 2.12 Custom analysis: A test for a specific mutation pre-
viously identified in a particular family (either in a clinical or
research laboratory), not necessarily in a gene for which the
laboratory offers broad testing.
URD 3 TECHNOLOGY GUIDELINES
URD 3.1 The choice in technology is dependent upon the type
of mutation and the mutational spectrum of the disorder.
Most of the rare disorders are composed of a large mutational
spectrum, including a variety of types of mutations in either a
single gene or multiple genes. Therefore, a targeted approach
to mutational detection for common mutations, such as in
cystic fibrosis transmembrane conductance regulator (CFTR)
testing, usually is not the case (see “CFTR Mutation Testing” in
the Disease/Phenotypic-Specific section of the ACMG Stan-
dards and Guidelines for Clinical Genetics Laboratories). For
rare disorders, either sequencing the entire coding region and
intron/exon boundaries, or a combined approach of scanning
for mutations using various platforms and confirming muta-
tions by sequencing, is generally indicated.
URD 3.2 Sequencing
URD 3.2.1 Section G13 of the ACMG Standards and Guidelines
for Clinical Genetics Laboratories addresses sequencing.
URD 3.2.2 An excellent adjunct to these guidelines is pub-
lished by the Clinical and Laboratory Standards Institute (CLSI
– formerly NCCLS), entitled MM9-P: Nucleic Acid Sequenc-
ing Methods in Diagnostic Laboratory Medicine (December
2004).
URD 3.2.3 For sequencing, it is essential to use sequence
analysis software and compare the patient sequence to the
wildtype. Inspection of chromatograms for heterozygous
positions is insufficient. The software used must support
assembly of contigs for analysis, including both forward and
reverse directions of fragments sequenced and any overlap-
ping fragments, the cDNA reference sequence, and the
genomic reference sequence.
URD 3.2.4 These guidelines address the unique aspects of in-
troducing testing for ultra-rare disorders directly into a CLIA-
certified laboratory. Under no circumstances is a CLIA-certi-
fied laboratory permitted to utilize a core sequencing facility or
other research laboratory to perform this testing.
URD 3.3 Scanning
URD 3.3.1 Sections of the ACMG Standards and Guidelines
for Clinical Genetics Laboratories that address scanning tech-
nologies include: Denaturing Gradient Gel Electrophoresis
(DGGE), G9; Protein Truncation Testing (PTT), G10; Sin-
gle Strand Conformational Polymorphism (SSCP), G11;
Heteroduplex Analysis (HA), G12; and Denaturing High
Performance Liquid Chromatography (DHPLC), G18. For
scanning technologies, it is important to determine the an-
alytical sensitivity and specificity.
URD 3.4 Limitations of Non-Quantitative Sequencing and
Scanning Methods
URD 3.4.1 It is important to understand that these methods
will detect point mutations including small deletions and small
insertions, nonsense, missense, splicing mutations, single nu-
cleotide polymorphisms (SNPs), and unclassified variants, but
they will not detect large gene deletions or duplications or
other gross genomic rearrangements.
URD 3.4.2 Therefore, in order to provide comprehensive mu-
tation detection analysis for those genes in which this issue is
relevant, it is recommended that the laboratory consider de-
veloping a technical platform to identify the presence of such
gross alterations. Many such platforms are available, including
southern blot, fluorescent in situ hybridization (FISH), multi-
plex gene dosage analysis, reverse transcription polymerase
chain reaction (PCR), long-range PCR, real time quantitative
PCR using SYBR® green or fluorescent probe technology, and
multiplex ligation probe amplification (MLPA). This is not an
inclusive list and continues to evolve. A combination of tech-
nologies may be useful as confirmatory testing. Most of these
technologies require in-house development of the assay. Thus,
it is recommended that only highly experienced laboratories
undertake this challenge.
URD 3.5 Linkage Analysis
URD 3.5.1 In situations in which direct mutation identifica-
tion may not be possible (e.g., when a critical individual in a
family is deceased or otherwise unavailable, or when a multi-
exon deletion underlies a disorder), it is sometimes possible to
use linkage analysis to identify the disease allele segregating in
a family, and to use that information for diagnostic and prena-
tal testing purposes. In such cases, as many informative mark-
ers as necessary to identify the disease allele must be typed in all
relevant, available family members. Reported results should
reflect the uncertainty due to recombination inherent in all
linkage-based studies.
URD 3.6 It is important to recognize that the laboratory is
responsible for validation of all analytical components of test-
ing (see Section C8 of ACMG Standards and Guidelines for
Clinical Genetics Laboratories on Test Validation).
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URD 4 PERSONNEL
URD 4.1 The standards for laboratory personnel involved in
testing for ultra-rare genetic diseases should be essentially
equivalent to those in other areas of diagnostic molecular ge-
netic testing, as described in the ACMG Standards and Guide-
lines for Clinical Genetics Laboratories. Laboratory directors
should have a doctoral degree and appropriate training and
experience in clinical molecular genetic testing, as evidenced
by board certification in clinical molecular genetics, molecular
genetic pathology, or equivalent subspecialty expertise. Tech-
nical staff should possess sufficient case experience in molecu-
lar testing for certification or eligibility by the National Cre-
dentialing Agency (NCA) as a molecular biology specialist or
equivalent. Since most ultra-rare disease tests are sequence-
based, directors and staff should have sufficient experience in
the performance and interpretation of DNA sequencing assays
for both known and unknown mutations.
URD 5 TEST VALIDATION
URD 5.1 Clinical Validation of Testing
URD 5.1.1. The issue of clinical validation in URDs is unique:
The accepted guidelines for determining clinical validity for
the more common hereditary disorders are not directly appli-
cable due to the paucity of data for any particular rare disorder.
It is thus incumbent on each laboratory choosing to add an
ultra-rare disorder diagnostic test to its menu to perform a
thorough review of all available literature on the gene and mu-
tational spectrum in the disease. Ideally, at least two peer-re-
viewed publications should provide very strong evidence of the
involvement of the particular gene in the development of the
disease. In some cases only a single publication with an exten-
sive data set may have been published. Data must be sufficient
to determine, with some level of confidence, the sensitivity and
specificity of the test to be offered. Particular caution should be
taken when considering disorders in which: 1) the phenotype
may be due to the interaction of multiple loci; 2) mutations in
more than one gene can lead, independently, to the phenotype;
3) there are phenocopies of the disorder that are not due to the
gene being tested; or 4) the clinical presentation associated
with mutation in the gene is poorly defined.
URD 5.2 Analytical Validation
URD 5.2.1 Ultra-rare genetic disease testing requires mutation
analysis of specific genes for specific genetic disorders. These
tests do not target a particular mutation (apart from custom
mutation analysis described in Section URD 10); rather, they
are aimed toward detecting the presence of any mutation
within the gene being analyzed. For the majority of ultra-rare
genetic diseases, the mutations identified are rare and do not
occur commonly among patients. A large number of patients
have their own private mutations that are not described in any
other patients. For this reason, test validation cannot be per-
formed for each and every single mutation that could possibly
occur in a particular gene.
URD 5.2.2 As discussed in Section URD 3, several different
mutation detection methods exist and are used in different
laboratories. The most commonly used method currently is
DNA sequencing. Other methods used are described in Section
URD 3.3.1 and detailed in the ACMG Standards and Guidelines
for Clinical Genetics Laboratories. Regardless of the mutation
detection methodology used, all laboratories are required to
validate their particular assay first on a number of DNA sam-
ples with known sequence information and then on a series of
blinded samples containing a diverse array of mutations and
sequence changes, as well as blinded specimens with no
changes. Blinded samples for validation testing can be ob-
tained from research laboratories as well as from other clinical
laboratories that may be offering the test. Records of test vali-
dation should be available for review by inspectors from agen-
cies providing laboratory certification.
URD 5.2.3 Given the fundamental rarity of the diseases in
question, obtaining multiple blinded samples may not be
possible. In this situation, if the test methodology is one in
which the laboratory is highly experienced and if successful
results have been demonstrated using negative controls, the
laboratory may offer a new test while continuing to review
and tabulate test results for concordance with clinical diag-
nosis and family history.
URD 5.2.4 It is equally important in analytical validation to
review and document all available knowledge about the locus
to be tested, and to update this survey periodically. Critical
points to be considered in test design include the existence of
any pseudogenes or other homologous genes, and the loca-
tions of all reported polymorphisms.
URD 5.2.5 For custom mutation analysis, in which a sequenc-
ing-based test is set up to confirm a mutation identified in a
research setting, the test can be considered to be “self-validat-
ing.” When analyzing a sample known to contain the mutation
being tested for, this test acts as its own positive control and
allows for the analytical validation of the test for that particular
mutation. A positive control therefore always exists for the
custom mutation analysis tests except in those instances in
which a research finding cannot be confirmed. Custom muta-
tion analysis should only be performed by laboratories highly
experienced in performing DNA sequence-based tests.
URD 6 QC STANDARDS AND QA PROGRAMS
URD 6.1 The quality control and quality assurance guide-
lines published by ACMG for routine molecular genetic
tests also apply to ultra-rare disorders, with certain consid-
erations related to the rarity of the disorders.
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URD 6.2 Positive and Negative Controls for Ultra-Rare Disor-
ders
URD 6.2.1. Positive and negative controls for sequencing: Pos-
itive controls are not required for sequence-based tests. Nega-
tive controls may need to be sequenced if a concurrent com-
parison is needed to help distinguish between assay artifacts
and a true difference.
URD 6.2.2. Positive and negative controls for mutation scan-
ning technologies: A negative control for every fragment
should always be tested for comparison to the test sample. It is
not necessary or even possible to obtain a positive control for
every potential mutation to be detected, but representative
positive controls may be run periodically as needed for quality
assurance. For some mutation scanning methods, a positive
control can be considered to be a sample in which any sequence
change (either a mutation or a polymorphism) is known to be
present in the amplicon to be tested. As it is unlikely the labo-
ratory will obtain a positive control for every single amplicon
being tested for a particular gene, such testing can be per-
formed in the absence of positive controls, but effort should be
made to include such controls as they become available.
URD 6.2.3. Positive and negative controls for other methods:
Rare or ultra-rare disorders sometimes have hotspots or
founder mutations that are amenable to simple tests such as
restriction digestion, amplicon length analysis, or allele-spe-
cific priming. In such cases, both positive and negative controls
are readily available and should always be concurrently tested.
URD 6.2.4 Positive and negative controls for custom (known
mutation) tests: In the special situation of custom PCR-based
testing for a known mutation, if the mutation was identified
elsewhere, the laboratory should make every effort to obtain a
positive control and must attach a caveat to the result if one was
not available. This control is necessary to confirm the accuracy
of the reported mutation, to test the sensitivity of the detection
method to be used, and to confirm that the primers can am-
plify the mutant allele in that family.
URD 6.2.4.1 When known-mutation testing is used for prena-
tal diagnosis and the fetus is at risk for homozygous recessive
mutations, it is equally important to confirm that the primers
being used can amplify the parents’ normal alleles. Thus both
parents must be available as controls, even though another labo-
ratory has already demonstrated that they are heterozygous.
URD 6.3 QA Programs Related to Methodology Shared
Among Different Tests
URD 6.3.1 Many different ultra-rare disorder tests performed
in a given laboratory may use the same methodology, e.g., se-
quence analysis. Certain ongoing QA evaluations such as staff
competence and software performance can be focused broadly
on the methodology level. For example, technicians who are
evaluated on a subset of ultra-rare disorder tests may be al-
lowed to perform technical aspects of other tests using the
same methodology.
URD 6.4 Proficiency Testing (PT)
URD 6.4.1 Proficiency testing for ultra-rare disorders is
unique in that locus-specific PT is impractical due to: 1) the
very small numbers of analyses of any given gene that may be
done by a particular laboratory each year; 2) the large number
of different genes that may be offered by one laboratory; and 3)
the fact that PT for the identification of specific mutations in
any given gene is not broadly representative due to the private
nature of most mutations in genes associated with ultra-rare
disorders. Therefore, PT in the ultra-rare disorders laboratory
should be designed to test the proficiency of the laboratory’s
use of the methods for mutation detection, as well as its ability
to detect the different classes of mutations for which services
are offered. For example, if the laboratory uses sequencing,
restriction digestion, heteroduplex analysis, and quantitative
PCR to identify and/or confirm mutations, the PT program for
the laboratory should require that 1-3 blinded samples for each
methodology should be tested semiannually.
URD 6.4.2 In addition to methodological PT, laboratories are
encouraged to establish a locus-specific PT program for any
gene that is tested regularly at significant volume. It is appro-
priate to set up a rotation of locus-specific PT in proportion to
the volume of particular tests performed by the laboratory. A
locus-specific PT program can also serve as the methodological
PT program.
URD 6.4.3 Specimens for methodological or locus-specific PT
programs can be independently arranged on an external or
internal basis. Formal PT programs are not available for ultra-
rare disorders, and partners for interlaboratory exchanges may
not be available. If any other laboratories, even internationally,
offer testing for the ultra-rare disorder loci, blinded exchanges
should be established if possible. If another clinical laboratory
partner is not available, specimens could be sent to a genotyp-
ing/sequencing core facility in one’s institution or elsewhere.
Such external comparisons are superior because they not only
monitor the reproducibility of results within a laboratory but
also permit comparison of alternate test design, including al-
ternate primer binding sites. If the only source of PT specimens
is internal, chosen specimens can be resubmitted for a full-
blinded analysis. Internally obtained PT specimens can be
tested by different technicians and analysts, using any different
sequencing apparatus and software that are in place, to evalu-
ate as many components of the testing process as possible.
URD 6.5 Additional QA Opportunities
URD 6.5.1 Other opportunities to monitor and improve qual-
ity may include programs such as tracking the performance of
any confirmatory or duplicate tests routinely performed, or
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periodically assessing the observed versus expected ratio of
positive results in light of the patient population being tested.
URD 7 TEST INTERPRETATION
URD 7.1 Interpretation of Sequence Variants (Point Muta-
tions, Small Insertions and Deletions)
URD 7.1.1 Interpretation of sequence variants can be relatively
straightforward, but it can also be challenging. The ACMG has
developed a position statement entitled “Recommendations
for Standards for Interpretation of Sequence Variations” to
help laboratories with interpretation and reporting.2 Three
factors are critical in assessing whether a variant is disease-
causing or benign: 1) whether it has been reported in the liter-
ature/database; 2) whether it has been associated with disease;
and 3) whether the type of mutation is expected to cause dis-
ease. Thus, the following categories must be defined: 1) re-
ported and known to cause disease; 2) reported and known to
be benign; 3) unreported, but expected to cause disease; 4)
unreported, and unknown whether it would cause disease; and
5) unreported, but probably does not cause disease.
URD 7.1.2 Once a variant has been identified using a sequenc-
ing alignment program, the next step is to identify it with the
appropriate nomenclature.3 It is critical that laboratories iden-
tify and utilize the appropriate cDNA reference sequence for
naming mutations, and include this information in the muta-
tion analysis report. If alternative numbering systems or alter-
nate stop codons have been published, the laboratory obvi-
ously must bear this in mind when reviewing publications and
databases, and also provide a note of explanation in the final
report.
URD 7.1.3 Following appropriate naming of the variant, a mu-
tation database search should be done in general databases,
including human genome mutation database,4 and human ge-
nome variation (HGV) databases,5 and locus-specific data-
bases. These databases are extremely useful in providing im-
portant information to laboratories to allow appropriate
interpretation of variants. This information includes a thor-
ough characterization of the variant, including the nucleotide
change, the nucleotide position, amino acid changes and
codon position, and frequency in the affected population.
Other useful information provided in some instances is
whether or not the variant has been reported in the unaffected
population. Laboratories must explore the databases and liter-
ature for assessing variants and determining whether they have
been previously reported and thus are recurrent.
URD 7.1.3.1 Public databases of gene-specific mutations may
be out-of-date, and thus not contain more recently described
mutations. In addition, the databases may reference multiple
publications that are actually in conflict, e.g., some claiming
that a particular sequence variant is associated with disease,
while others claim that the variant is a nondisease associated
polymorphism. Databases that are not updated regularly may
contain information that is actually incorrect. For example, a
particular sequence variant may first be considered benign and
later be discovered to be a risk factor. The subsequent papers
showing that the variant was actually disease-associated may
never have been referenced in the database (or vice versa). The
laboratory should exercise caution in relying on databases to
interpret the meaning of an observed variant and reflect this in
the reporting of results.
URD 7.1.3.2 In numerous cases, laboratories will uncover
novel variants during clinical testing. It is important that these
variants be as well-defined as possible by the laboratory and
that the laboratory report this information back to the data-
bases. Databases are publicly available as a resource. Laborato-
ries are encouraged to develop policies and procedures to rou-
tinely send data to the appropriate database.
URD 7.1.4 Variants May Be Classified and Followed Up As
Follows:
URD 7.1.4.1. Truncating mutations: Leading to protein trun-
cation–including small insertions and deletions (and nonsense
mutations) that create a frame shift–are generally the type that
would be interpreted as disease-causing mutations. No addi-
tional follow up is necessary.
URD 7.1.4.2. Nonsense mutations: Generally lead to protein
truncation, but they can also form cryptic splice sites and may
be more difficult to interpret at the molecular level.6 Cryptic
splice sites can be evaluated by splice site predictor programs as
described in Section URD 7.1.4.3.
URD 7.1.4.3. Splicing mutations: Generally occur at the ca-
nonical GT:AG splice acceptor/splice donor sites, but they can
also occur farther into the intron or within the exon. The use of
splice site predictor programs may be useful in predicting
whether or not a base change surrounding the splice site will
affect splicing. These programs result in a score indicating
whether the base change will likely affect splicing. Some exam-
ples of splice site predictor programs accessible online, as of
September 26, 2005, include the Laboratory of Human Molec-
ular Genetics and Genomic Disorders’ Automated Splice Site
Analyses, and the Berkeley Drosophila Genome Project.7–9
Predictions can vary depending on the algorithm used. As a
diagnostic tool, the use of websites and software for this pur-
pose is equivalent to using general reference textbooks. The
only way to confirm splicing efficiency predictions clinically is
to examine the cDNA by sequencing. This means that an RNA
preparation will be necessary, and may require a second spec-
imen from the patient for analysis, except in cases in which
laboratories prepare RNA routinely. However, it may be the
case that the gene is not expressed in an accessible tissue.
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URD 7.1.4.4. Silent substitutions (third base wobble): Require
cautious interpretation because some have been demonstrated
to be pathogenic by causing abnormal splicing.6
URD 7.1.4.5 Missense substitutions: May actually be normal
variants, or may have deleterious effects that can be difficult to
recognize, such as causing a loss or gain of protein function due
to changes in the secondary structure of a protein or causing
spurious splicing of the mRNA due to the formation of a cryp-
tic splice-site. Missense changes that cannot conclusively be
determined to be either deleterious or benign should be re-
ported as sequence change of unknown clinical significance.
Some guidelines for interpretation of missense mutations are
noted below.
URD 7.1.4.5.1 The most fundamental classification of mis-
sense mutations is generally based on whether the amino acid
change is conservative or nonconservative. As a rule, noncon-
servative changes are more likely to be disease-causing muta-
tions. In addition, the laboratory should determine whether or
not the amino acid in question is evolutionarily conserved.
Evolutionarily conserved amino acids suggest that the amino
acid has an important functional role and that any change
would be detrimental. The position of the amino acid change
within the protein can also be checked. Amino acid changes
that occur at known functional domains are more likely to be
pathogenic.
URD 7.1.4.5.2 Another useful strategy to assess whether a variant
tracks with disease is to analyze other family members, including
both those affected and those unaffected. Frequently, follow-up is
lost due to various reasons, including family relationships. How-
ever, it is recommended that laboratories consider requesting
samples from other family members when appropriate.
URD 7.1.4.5.3 While these approaches are classical, there are
newer ways to address this question, including using predictive
software tools for protein modeling to determine how changes
might be detrimental to protein function. Another approach is
use of predictive software tools, such as evolutionary trace (Li-
chtarge Laboratory, Baylor College of Medicine), to determine
how likely the change is to affect protein function. Some of
these tools are presently in evaluation and may not be available
for clinical laboratories at this time.
URD 7.1.4.5.4 The ultimate test for any of these unclassified
small variants would be the development of a functional assay
to test whether or not the change affects protein function.
There are very few examples of such a test in a clinical labora-
tory at the time of this writing. Functional studies are usually
beyond the scope of the clinical laboratory, but “partnering”
with research laboratories for this purpose may be feasible.
URD 7.1.4.6 Single nucleotide polymorphisms (SNPs) are re-
curring variations in coding or noncoding regions that have no
known or obvious disease-causing effect. If a single nucleotide
substitution is discovered in a patient, the laboratory must de-
termine if it is a recognized SNP of no clinical significance; this
can be done by searching public SNP databases10,11, by consult-
ing researchers studying that gene, and/or by examining a sig-
nificant number of normal sequences prospectively or retro-
spectively. If the change is concluded to be a common benign
variant, the basis of this conclusion should be stated in the
report. If the minor variant is seen in the general population
but is reported to be over-represented in the affected popula-
tion, a citation of the study should appear in the report. If the
change cannot be categorized as a known benign SNP, it
should be reported as an “unclassified variant” or “variant of
unknown significance.”
URD 7.1.4.6.1 The presence of nondisease associated SNPs in a
sequence should be reported because the allele may be discov-
ered in the future to be disease-associated. Furthermore, het-
erozygosity at any position in any gene is often useful and can
serve: 1) to assure that both alleles have been amplified and are
represented in the analysis; 2) as markers for linkage analysis in
families where applicable; 3) to evaluate a prenatal sample for
the presence of maternal cell contamination; and 4) to address
issues of sample-switching or nonpaternity/maternity. For
these reasons, it is recommended that the presence of heterozy-
gosity at SNP positions be noted in the mutation analysis re-
port. Either the location of the SNP (e.g., ivs2-106), or the
location along with the actual genotype (e.g., ivs2-106, g/a) can
be noted. One suggested format for commenting on SNPs
without distracting from the overall “positive” or “negative”
results would be to address SNPs in a separate section of the
report or footnote.
URD 7.1.4.6.2 The observation of apparent homozygosity for a
rare SNP allele with no obvious pathogenic consequences may
be worthy of comment, since such variants could later be de-
termined to have some associated risk, but it would be inap-
propriate to raise extreme concern. More to the point, in the
special situation when the possibility of a large deletion is al-
ready being considered in a nonconsanguineous family due to
the absence of heterozygous positions, the detection of appar-
ent homozygosity for a rare SNP allele could be another indi-
cation of a deletion and possibly serve as a marker for parental
studies.
URD 7.2 Interpretation of Gross Alterations
URD 7.2.1 Gross alterations (deletions, duplications, or rear-
rangements) can be detected in some sequencing assays, for
example by failure to amplify an X-linked gene in a male or by
detection of homozygosity for a mutation or polymorphism in
a proband that is not confirmed in the patient’s parents. Nu-
merous other strategies mentioned in section URD 3.4.2 are
designed for this purpose. With such tests, any result that is dif-
ferent from that obtained for the normal control is indicative of a
gross alteration and can usually be interpreted as pathogenic. Re-
sults that do not differ from the normal control are interpreted as
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grossly normal. In the case of a normal result, it is important to
state the sensitivity of the assay within the final report.
URD 7.2.2 Gross alterations are generally under-represented
in mutation databases. This is partly due to such mutation
types not being routinely tested for and reported.
URD 7.2.3 When a gross alteration is identified, its exact
boundaries are not generally defined. As a result, it is difficult
to assign a precise nomenclature. Such abnormalities are gen-
erally described simply as, for example, “deletion of exon (#) in
gene (name).”
URD 7.3 Interpretation of a Normal Result
URD 7.3.1 When a normal result is obtained, it is important to
refer to the analytical sensitivity of the test and to state that an
undetected mutation may be present. This could be due to: 1)
the nature of the mutation, e.g., deletions; 2) the presence of
mutations outside of the coding regions that were not tested,
e.g., in the promoter region; 3) the presence of a mutation in a
totally different gene; 4) the presence of unexpected variation
in a particular patient at a primer binding site, leading to allele-
drop-out or preferential amplification of a competing allele; or
5) mosaicism.
URD 8 TYPE OF TESTING
URD 8.1 The type of testing depends upon the type of disorder
and inheritance pattern. Rare disorder testing may include di-
agnostic testing, carrier testing, and prenatal testing. Popula-
tion screening, such as carrier testing for CF, is less likely for ultra-
rare disorders, although screening for a mutation in the spouse of
an individual known to be a heterozygote for a rare autosomal
recessive disorder is occasionally requested. Initial testing may in-
clude confirmation of research findings in a clinical laboratory.
URD 8.2 Prenatal testing carries high liability and should be
undertaken with caution, particularly for ultra-rare disorders
for which limited clinical validation data are available. Specific
guidelines for prenatal testing should be followed (see Section
G19 of the ACMG Standards and Guidelines for Clinical Genet-
ics Laboratories).
URD 9 PRE- AND POST-TEST ISSUES
URD 9.1 Pretest and post-test issues such as specimen require-
ments, transport, patient identification, family identification,
criteria for rejection, etc., are generally the same for ultra-rare
disorders as for other molecular genetic tests, with the follow-
ing points of emphasis:
URD 9.2 Pre-Test Considerations
URD 9.2.1 Test description and/or informed consent docu-
ment: A test description and/or test-specific informed consent
document can help both the patient and the ordering physician
understand the appropriate uses and limitations of the test.
The document should define the name of the gene or genes to
be tested; the regions (exons) to be tested; the clinical disorders
associated with that gene; and the usual indications for testing;
such as differential diagnosis, carrier test, or prenatal diagno-
sis. The document should state both the clinical sensitivity and
analytical sensitivity, for example “60% of patients with this
disease have mutations in the XYZ gene. Over 90% of pub-
lished mutations in the XYZ gene, to date, would be detected
by sequence analysis of exons 2, 3, and 4.”
URD 9.2.2 Who can submit tests: Like all genetic tests, URD
tests may be ordered by a physician of any specialty and may be
submitted as referred tests from general pathology laborato-
ries. Patients cannot submit tests directly.
URD 9.2.3 Clinical history and family history: Laboratories
should request any background information that is necessary
for interpreting the test result. At a minimum, this information
would typically indicate if the patient is affected with the disorder
or has a positive family history, and whether the family has a
known mutation. In some disorders, priorities for the analysis of
different genes or exons may depend on the phenotype, the ethnic
group, or the inheritance pattern.
URD 9.2.4 Special preanalytical criteria for identification of
specific mutations identified elsewhere:
URD 9.2.4.1 Information provided about the mutation must
be sufficiently unambiguous to identify the gene and nucleo-
tide(s) to be tested. Missense and stop mutations should be
described at the DNA level as well as the protein level. Refer-
ence sequences should be given. Numbering conventions, such
as with or without a leader peptide, should be stated. Sur-
rounding sequence is very helpful.
URD 9.2.4.2 The importance of retesting a positive specimen
should be presented to the referring physician. This practice
not only guards against communication errors, historical
changes in the numbering of exons, and inconsistency in the
numbering of nucleotides and codons, but also allows the lab-
oratory to absolutely rule out allele dropout of the abnormal
allele which can occur through family-specific polymorphisms
in primer sites, thus providing a level of customized QC not
otherwise available. Although allele dropout is rare, the ease of
doing this simple QC step makes it compelling.
URD 9.3 Post-Test Considerations
URD 9.3.1 Interpretation of the clinical significance: See sec-
tion URD 7.
URD 9.3.2 Report contents: Elements of routine molecular
laboratory reports as presented in the ACMG Standards and
Guidelines for Clinical Genetics Laboratories, section G17, are
applicable to ultra-rare disorders as well. They include patient
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name; other patient identifiers; specimen type; draw date; re-
ceived date; accession number; family number (if used); test
ordered (disease name and gene name); clinical status or rea-
son for test; method; result; interpretation; limitations; recom-
mendations. Tests for ultra-rare disorders or any sequencing
test should identify the reference sequence used and the loca-
tion in that sequence of nucleotide 1 and codon 1 in relation to
the initiator ATG. Any mutations or polymorphisms identified
should be stated using standard nomenclature on both the
DNA level and the protein level.
URD 9.3.3 Transmission of report Laboratories should be aware
that it is increasingly common for hospital and reference lab da-
tabases to truncate or summarize lengthy results. It is wise to pro-
vide a succinct, easily excerpted statement of critical information,
such as negative with limitations, indicating that important
comments are included.
URD 9.3.4 Sample Reports: (See Appendix)
URD 10 CUSTOM ANALYSIS
URD 10.1 Custom mutation analysis applies to situations in
which a disease mutation has been identified in a patient in a
research setting and needs to be confirmed in the clinical set-
ting so that the results may be: 1) released to the patient/family
and/or referring physician for purposes of diagnosis and treat-
ment; 2) used for further testing in other family members to
determine mutation status; and 3) utilized in prenatal testing
situations. Custom mutation analysis applies to those genetic
disorders in which only rare private mutations have been de-
scribed (the majority of ultra-rare genetic disorders), for which
testing is not routinely available, and to those more common
genetic disorders (e.g., cystic fibrosis, Duchenne muscular dys-
trophy, Canavan disease, to name a few) in which an unco-
mamon/rare mutation, not routinely tested for, is found to be
present in a patient or family. GeneTests12 lists laboratories
that provide a custom mutation analysis service, i.e., laborato-
ries that will clinically confirm mutations identified in research
laboratories.
URD 10.2 The clinical validation of custom tests for ultra-rare
disorders or other private mutations is the obligation of the
researcher who performed the initial study. In performing a
confirmation of a research laboratory finding, the clinical lab-
oratory is responsible for only the analytical validation, as de-
scribed in Sections URD 5.2.5 and URD 10.3. The laboratory
report may address only the presence or absence of the muta-
tion and refer to the researcher’s interpretation for causative
association with disease.
URD 10.3 For purposes of mutation confirmation, it is essen-
tial that the test be performed on a new sample obtained from
the patient and sent directly to the clinical laboratory, i.e., not
a sample that was received and processed by the research lab-
oratory that originally identified the mutation. For analytical
validation, it is important for the clinical laboratory to confirm
the mutation in the original proband prior to performing any
testing on additional family members, and particularly prior to
any prenatal testing. In the event of limited time it is acceptable
to perform the test on the proband (for confirmation pur-
poses) and the additional family member/prenatal sample at
the same time. If the mutation finding cannot be confirmed by
the clinical laboratory on the original proband, this needs to be
stated in the patient’s report and no reporting can be made of
any additional family members/prenatal samples until the dis-
crepancy in the proband’s result has been clarified. In some
instances the original proband is deceased and mutation con-
firmation cannot be performed on a new sample. In such in-
stances the following options can be pursued:
URD 10.3.1 Family members who are obligate carriers of the
mutation can be used to establish the clinical mutation confir-
mation in that family.
URD 10.3.2 If no family member can be identified in whom
mutation confirmation can be performed, then mutation test-
ing on at-risk family members is performed in the absence of
formal mutation confirmation. If the mutation is found to be
present in any family member being tested, the familial muta-
tion for that family is confirmed and can be reported. How-
ever, if the family member being tested is found not to carry the
mutation, it is very important to state in the report that a pos-
itive control from that family was not available for the muta-
tion being tested. The caveat should emphasize that the results
being reported are dependent on the accuracy of the informa-
tion received from the previous laboratory.
URD 10.3.3 At the very minimum, in the absence of a new
positive control specimen from the family, it is important to
obtain a DNA aliquot from the previous laboratory to serve as
a positive control for a custom test. This permits technical
validation of the primers and conditions for detection of that
mutation, although it does not rule out possible misidentifica-
tion of that original research specimen.
URD 10.4 It is important that the clinical laboratory has suffi-
cient information about the mutation to be tested prior to
setting up the mutation-specific assay. Certain mutations may
not be amenable to detection using the techniques available to
the clinical laboratory, for example, the identification of large
intragenic gene deletions by routine PCR-based methods. In-
formation regarding the mutation to be tested, what gene it
occurs in, where it occurs in the gene, and, if possible, assay
conditions used by the research laboratory to identify the mu-
tation should be provided to the clinical laboratory prior to
developing the mutation-specific assay. It is important to make
sure that the mutation nomenclature provided to the clinical
laboratory is clear and unambiguous.
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URD 10.5 For single base changes and small deletions/inser-
tions, DNA sequencing is the appropriate technique to be used
for confirming a mutation in a custom mutation analysis. A
PCR amplicon is generated that contains the region of the mu-
tation and is sequenced in a double-stranded fashion. It is im-
portant to keep in mind that certain areas of the genome are
harder to analyze (such as GC-rich regions or regions of repet-
itive DNA) and therefore sufficient time needs to be allocated
to setting up custom mutation tests. Four to six weeks is generally
adequate time to set up such tests and takes into account potential
problems that may be encountered. Once a mutation-specific as-
say has been developed, testing of additional family members is
easier and faster (2-3 weeks) and may be accomplished by a less
direct method, such as restriction digestion or a scanning technol-
ogy.
URD 10.6 Confirmation of Negative Results from a Research
Laboratory
URD 10.6.1 Mutation confirmation for custom genetic tests
usually is requested to confirm a positive result identified in a
research laboratory. However, to ensure the accuracy of both
positive and negative results from a research laboratory, the
research laboratory should be encouraged to have the clinical
laboratory confirm the result on all family members, regardless
of whether the family member was found to have the mutation
or not. In such cases, analysis in the clinical laboratory will
likely only be performed for the specific mutation in the family
that was identified by the research laboratory, and the reported
results should reflect that a full analysis of the gene was not
accomplished. Thus, mutations elsewhere in the gene would
not have been identified by the analysis performed by the clin-
ical laboratory.
URD 10.6.2 It is rarely requested that a clinical laboratory con-
firm negative results for a research participant on whom no
mutation was found after a thorough research evaluation of the
disease gene. In most cases, confirmation of negative research
results in this situation will need to wait until a clinical labora-
tory offers testing of the disease gene on their usual test menu.
Research laboratories should be encouraged to translate re-
search testing into a clinical laboratory as soon as the test is
deemed clinically valid. Once clinical testing is available, re-
searchers should be encouraged to pursue clinical confirma-
tion of negative results.
URD 11 PITFALLS
URD 11.1 The use of different mutation nomenclatures by
different laboratories when numbering is performed using dif-
ferent reference sequences: This is extremely important for
custom mutation testing purposes to enable the correct re-
gion of the gene to be targeted for mutation testing. It is
important to make sure that there is no discrepancy in the
mutation nomenclature information and for this reason,
adhering to the recommendations made for mutation no-
menclature is strongly recommended.3,13
URD 11.2 Observation of a rare mutation in the homozygous
state in an autosomal recessive disease situation: In the absence
of known consanguinity, the possibility of a deletion on one
allele resulting in hemizygosity for the particular mutation (as
opposed to homozygosity) should be considered. Similarly,
interpretations of homozygosity for any rare polymorphism at
any diploid locus should also be considered as possible hall-
marks of deletions.
URD 11.3 Observation of homozygosity, or inability to con-
firm a mutation identified in a research laboratory: This result
may be due to the presence of a polymorphic position
within the primer sequence being used to amplify the DNA
fragment. In such cases, it is necessary to repeat the analysis
using a second set of primers positioned away from the
original primer pair. It is useful, but far from foolproof, to
check SNP databases when designing primers. Laboratories
should use disclaimers on their reports that identify such
pitfalls.
URD 11.4 Interpretation of mutation/sequence change find-
ings can be difficult (e.g., missense changes, noncoding region
changes, silent changes). The presence of a database of muta-
tions and polymorphisms for all genes being tested will help. In
some cases it is necessary to defer to the research laboratory
from which the mutation information originated when inter-
preting such results. Clinical laboratories should be cautious
about deferring to research laboratories.
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APPENDIX
Sample Laboratory Reports For Ultra-Rare Disease Testing
SAMPLE 1: Complete Gene Sequencing with Negative
Results and Heterozygous Positions
Test: Sequence analysis of the XXX gene
Indication for Testing: Suspected diagnosis of ________
syndrome
Method: The 20 coding exons and the flanking intronic re-
gions of the gene were amplified by PCR and sequenced in two
directions. The reference mRNA sequence is NM_xxxxxxxx,
with codon 1 corresponding to the start ATG and nucleotide 1
corresponding to the A.
Result: No XXX gene mutation was detected.
Details: Several heterozygous positions were noted, consis-
tent with the detection of two normal alleles. At codon 255,
both TAT and TAC were present. This is a known polymor-
phism of no apparent clinical significance, since both se-
quences encode tyrosine. At codon 871, both CCA (proline, P)
and CGA (arginine, R) were present. P871R is reported to be a
nondisease associated normal variant (Author et al., 1999).
Heterozygosity was also seen at a noncoding position, c.428-15
(IVS3-15), which has no apparent effect. The presence of these
heterozygous positions confirms that two alleles were present
and excludes the possibility of a complete deletion of one allele.
Interpretation: No mutation associated with ______ syn-
drome was detected in the gene of this patient. This result does
not exclude the diagnosis of this syndrome. Mutations in
_________ are found in 60% of patients with _______ syn-
drome and a positive family history, and in 35% of isolated
cases (Author et al., 2000). The interpretation is based on the
current understanding of the genetics of ________ syndrome.
Limitations: Only the coding regions of the XXX gene and
immediate flanking intron sequences were examined. Changes
in the promoter region, farther into the introns, or in other
noncoding regions of the gene, would not be detected. The
sensitivity of DNA sequencing is over 99% for the detection of
nucleotide base changes, small deletions, and insertions in the
regions analyzed. Mutations in genes other than XXX would
not be identified. Multiple exon deletions, multiple exon inser-
tions, and complete deletion of one allele may not be identified
using these methods. Other types of rare genetic variation can
interfere with this analysis.
References:
SAMPLE 2: Complete Gene Sequencing with Negative
Results and No Heterozygous Positions
Test: Sequence analysis of the XXX gene
Indication for Testing: Suspected diagnosis of ________
syndrome
Method: The 12 coding exons and the flanking intronic re-
gions of the XXX gene were amplified by PCR and sequenced
in two directions. The reference mRNA sequence is
NM_xxxxxxxx, with codon 1 corresponding to the start ATG
and nucleotide 1 corresponding to the A.
Result: No XXX gene mutation was detected.
Details: No heterozygous positions were observed. If
present, heterozygous normal polymorphic positions serve to
rule out gross gene deletions. Deletions are known to occur in
_______ syndrome in over 10% of cases. Furthermore, this
patient’s sequence included an apparently homozygous G at
position c.428-34 (IVS3-34). This is a change from the proto-
typic T that we have not observed in over 100 control and
patient sequences. The presence of G at IVS3-34 is not thought
to be a causative mutation, but it can be taken as an additional
indication for deletion testing, since a rare sequence change is
unlikely to appear homozygous unless the patient’s parents are
consanguineous.
Interpretation: No mutation associated with ______ syn-
drome was detected in the XXX gene of this patient. This result
does not exclude the diagnosis of this syndrome. Sequence
mutations in XXX are found in 60% of patients with _______
syndrome and a positive family history, and in 35% of isolated
cases (Author et al., 2000). Testing of the patient’s parents for
the IVS3-34 can be performed to clarify the presence of a de-
letion in this patient. Alternatively, deletion analysis for this
gene can also be considered if available. This interpretation is
based on the current understanding of the genetics of
________ syndrome.
Limitations: Only the coding regions of the XXX gene and
immediate flanking intron sequences were examined. Changes
in the promoter region, farther into the introns, or in other
noncoding regions of the gene, would not be detected. The
sensitivity of DNA sequencing is 99% for the detection of nu-
cleotide base changes, small deletions and insertions in the
regions analyzed. Mutations in genes other than XXX would
not be identified. Multiple exon deletions, multiple exon inser-
tions, and complete deletion of one allele may not be identified
using these methods. Other types of rare genetic variation can
interfere with this analysis.
References:
SAMPLE 3: Gene Scanning and Sequencing with
Positive Results
Test: Mutation analysis of the XXX gene
Indication for Testing: Suspected diagnosis of ________
syndrome
Method: The 20 coding exons and the flanking intronic re-
gions of the XXX gene were amplified by PCR and screened for
mutations using denaturing high performance liquid chroma-
tography (dHPLC). Amplicons showing variations were se-
quenced in two directions. The reference mRNA sequence is
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NM_xxxxxxxx, with codon 1 corresponding to the start ATG
and nucleotide 1 to the A.
Result: Positive for two mutations: S320P and p.L1061fsX4.
Details: S320P (serine to proline at amino acid 320) is caused
in this patient by a T to C substitution at nucleotide position
c.958. This mutation has not been reported in other
__________ syndrome patients to our knowledge, but it
causes a nonconservative amino acid substitution in a critical
domain, at a position where serine is invariant in all verte-
brates. S320P has not been reported as a normal variation and
has not been observed in our analysis of over 50 normal alleles.
Thus, S320P is likely to be a causative mutation for ________
syndrome, although functional studies have not been done to
prove this conclusively. p.L1061fsX4 describes a frameshift
mutation in the leucine (L) codon 1061 caused by deletion of
the normal T at position c.3183. The frameshift leads to a pre-
mature termination 4 codons downstream. p.L1061fsX4 has
been previously reported in patients with _______ syndrome
(Author et al., 1995).
Interpretation: S320P and p.L1061fsX4 are assumed to be
the cause of ________ syndrome in this patient. The detection
of two mutations in the XXX gene confirms the diagnosis and
provides specific mutation information that can be used for
carrier testing and prenatal diagnosis in this family. In this
autosomal recessive disorder, the parents of this patient are
each assumed to carry one mutation, although new mutations
are possible. This interpretation is based on our current under-
standing of the genetics of ______ syndrome.
Limitations: The two mutations found are assumed to be on
opposite chromosomes, but this cannot be proven by sequenc-
ing. This assumption must be confirmed by testing the parents
of this patient prior to any additional testing in this family.
References:
SAMPLE 4: Complete Gene Sequencing with Results of
Unknown Significance
Test: Sequence analysis of the XXX gene
Indication for Testing: Suspected diagnosis of ________
syndrome
Method: The 5 coding exons and the flanking intronic re-
gions of the XXX gene were amplified by PCR and sequenced
in two directions. The reference mRNA sequence is
NM_xxxxxxxx, with codon 1 corresponding to the start ATG
and nucleotide 1 to the A.
Result: A variation of unknown significance was identified:
c.978 C to T (S326S). No other differences from the prototypic
normal sequence were observed.
Details: This patient is heterozygous for a C to T substitution
at nucleotide c.978, resulting in AGT instead of AGC at codon
326. Both sequences encode serine (S). This sequence change
does not appear to have been previously described in patients
with _______ syndrome and has also not been described as a
known polymorphism (benign sequence change) in the XXX
gene. Since the amino acid is not changed and a spurious splice
site does not appear to be introduced, it is possible that this
change is nonpathogenic, but functional studies have not been
performed to prove this conclusively.
Interpretation: No obvious pathogenic mutation was dis-
covered but an inconclusive finding is reported. Over 80% of
patients with classical ______ syndrome have obvious patho-
genic sequence mutations in the XXX gene. Testing of the pa-
tient’s parents for the c.978CT change, along with a thor-
ough physical examination for mild signs of ________
syndrome, may help determine the pathogenic nature of this
finding.
Limitations: Only the coding regions of the XXX gene and
immediate flanking intron sequences were examined. Changes
in the promoter region, farther into the introns, or in other
noncoding regions of the gene would not be detected. The
sensitivity of DNA sequencing is over 99% for the detection of
nucleotide base changes, small deletions and insertions in the
regions analyzed. Mutations in genes other than XXX would
not be identified. Multiple exon deletions, multiple exon inser-
tions, and complete deletion of one allele may not be identified
using these methods. Other types of rare genetic variation can
interfere with this analysis, but complete absence of one copy
of the XXX gene is ruled out by the observation of heterozy-
gosity at one or more positions.
References:
SAMPLE 5: Custom Testing for a Known Mutation with
Positive Results
Test: Custom analysis for a G403R mutation in exon 8 of the
XXX gene
Indication for Testing: Family history of ___________ syn-
drome. The mutation G403R was reported to have been de-
tected in this family in the research laboratory of Dr.
_____________, who has referred this patient to us for clinical
testing.
Method: Research results were provided indicating that a
member of this family has a GGC to CGC mutation in codon
403 (glycine to arginine) of the XXX gene, using mRNA refer-
ence sequence NM_xxxxxxxx and assigning codon 1 to the
start ATG with the inclusion of the cleaved signal peptide. The
G to C nucleotide change corresponds to position c.1207 in the
mRNA. Exon 8 was amplified by PCR and sequenced bi-direc-
tionally. Analysis was performed on a separate blood sample
from the patient sent directly to our laboratory. (In the event a
separate blood sample from the affected proband is not avail-
able: A DNA sample was provided by the researcher as a posi-
tive control, although an independent new positive control
sample was not available).
Result: The G403R mutation was found in the heterozygous
state in this patient.
Details: Testing of the patient’s blood sample (or: positive
control DNA sample provided by the researcher) allowed us to
demonstrate that the test method we designed could detect the
reported G403R mutation. The detection of this mutation in
the patient confirms the research laboratory’s finding in this
family.
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Interpretation: This patient has the G403R mutation previ-
ously reported to be in her family. This mutation has been
reported in the literature to be deleterious (cite reference), and
thus is interpreted as a disease-causing mutation. Genetic
counseling is recommended for this individual.
Limitations: Only the region immediately surrounding
codon 403 of the XXX gene was examined. Changes elsewhere
in the gene, or in other genes, would not have been detected.
(In the event a separate blood sample from the affected pro-
band is not available: As a separate patient sample could not be
tested, the presence of a sample mix-up in the research labora-
tory cannot be ruled out.)
References:
SAMPLE 6: Custom Testing for a Known Mutation with
Failure to Confirm
Test: Custom analysis for an R100X mutation in exon 4 of
the XXX gene
Indication for Testing: Family history of ___________ syn-
drome. The mutation R100X was reported to have been de-
tected in this patient in the research laboratory of Dr.
_____________, who has referred the family to us for clinical
testing. This patient is being tested as a positive control.
Method: Research results were provided indicating that this
patient has an AGA to TGA mutation in codon 100 (arginine to
stop) of the XXX gene, using mRNA reference sequence
NM_xxxxxxxx and assigning codon 1 to the initiator ATG. The
A to T nucleotide change corresponds to position c.298 in the
mRNA. Exon 4 was amplified by PCR and sequenced bi-direc-
tionally.
Result: Unable to confirm the presence of any mutation in
codon R100.
Details: Only the normal exon 4 sequence was seen. No het-
erozygous positions were detected elsewhere in the exon or
flanking intronic sequence; such positions, if present, would
have confirmed that two alleles were amplified. The same re-
sult was obtained using an alternate set of primers.
Interpretation: This patient is demonstrating discordant re-
sults between our laboratory and the research laboratory. Rare
genetic variants can interfere with this type of analysis, partic-
ularly in primer binding sites, so two different primer sets were
used. Neither set detected the reported mutation. Until this
discordance is resolved, this test will not be available for addi-
tional members of this family.
Limitations: Only exon 4 of the XXX gene was examined.




October 2005  Vol. 7  No. 8 583
